Safety and tolerability of peginterferon β-1a in patients with relapsing-remitting multiple sclerosis: Data from the pivotal phase 3 ADVANCE study

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2013
This article has no abstract
Epistemonikos ID: 9fc8c4c8862742c74495b1a97f18c8f5f66c8711
First added on: Apr 30, 2026